Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $820

Benzinga · 3d ago
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $798 to $820.